Analyst Price Targets — NKTR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 10, 2026 5:17 pm | — | BTIG | $151.00 | $52.00 | TheFly | Nektar price target raised to $151 from $118 at BTIG |
| February 10, 2026 2:16 pm | — | H.C. Wainwright | $165.00 | $52.62 | TheFly | Nektar price target raised to $165 from $135 at H.C. Wainwright |
| January 26, 2026 1:56 pm | Yasmeen Rahimi | Piper Sandler | $105.00 | $36.35 | StreetInsider | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' |
| December 16, 2025 5:48 pm | — | H.C. Wainwright | $135.00 | $51.17 | TheFly | Nektar price target raised to $135 from $120 at H.C. Wainwright |
| December 16, 2025 4:08 pm | Jay Olson | Oppenheimer | $115.00 | $50.43 | TheFly | Nektar price target raised to $115 from $98 at Oppenheimer |
| November 24, 2025 10:35 am | Roger Song | Jefferies | $121.00 | $54.28 | StreetInsider | Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies |
| September 18, 2025 7:55 pm | Roger Song | Jefferies | $99.00 | $58.74 | TheFly | Nektar price target raised to $99 from $69 at Jefferies |
| April 18, 2022 12:00 am | Mara Goldstein | Mizuho Securities | $6.00 | $4.74 | TipRanks Contributor | Nektar & Bristol Myers Halt Their Combination Therapy Trials |
| March 1, 2022 12:00 am | Jessica Fye | J.P. Morgan | $17.00 | $10.98 | TheFly | Nektar price target lowered to $17 from $24 at JPMorgan |
| November 8, 2021 12:00 am | Aydin Huseynov | Ladenburg Thalmann & Co. | $20.00 | $14.65 | TheFly | Nektar upgraded to Buy from Hold at Benchmark |
Latest News for NKTR
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive. What To Do Next: For more information, submit a form at Nektar…
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no…
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv- 01951, is on behalf of a class consisting of all persons and entities other than…
LOS ANGELES, March 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NKTR.
U.S. House Trading
No House trades found for NKTR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.